Jazz Pharmaceuticals plc (JAZZ) announced that it has entered into a definitive agreement with U.K.-based biotech Redx Pharma to acquire global rights to the latter’s preclinical KRAS (Kirsten rat sarcoma virus) inhibitor program.Per the agreement, Jazz will make an upfront payment of 10milliontoRedxtogainallrights,patentsandinterestrelatedtoitsproprietaryKRASinhibitorprogram,includingitsG12Dselectiveandpan−KRASmolecules.Further,Redxisentitledtoreceiveupto870 million in the ...